U.S. markets close in 4 hours 40 minutes

Lexicon Pharmaceuticals, Inc. (LXRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.4800-0.0600 (-1.32%)
As of 11:17AM EDT. Market open.

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place
The Woodlands, TX 77381-1160
United States
281 863 3000
http://www.lexpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees78

Key Executives

NameTitlePayExercisedYear Born
Mr. Lonnel CoatsPres, CEO & Director1.15MN/A1965
Mr. Jeffrey L. Wade J.D.Exec. VP of Corp. & Admin. Affairs and CFO655.18kN/A1965
Mr. Brian T. CrumVP, Gen. Counsel & Sec.536.92kN/A1973
Dr. Alan J. MainExec. VP of Innovation & Chemical Sciences560.17kN/A1954
Dr. Robert J. LefkowitzConsultant & Independent Director50kN/A1944
Mr. James F. TessmerVP of Fin. & AccountingN/AN/A1960
Chas SchultzExec. Director of Corp. Communications & Patient AdvocacyN/AN/AN/A
Dr. Craig B. Granowitz M.D., Ph.D.Sr. VP & Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Corporate Governance

Lexicon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 10. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.